140 Recruiting Trials

Clinical Trials
for Cancer in Nevada

140 clinical trials for Cancer are currently recruiting participants at study sites in Nevada. Study-related care is provided at no cost.

140
Recruiting trials
122
Study sites
8
Cities
85
Industry-sponsored
40
Phase 2
82
Phase 3

Cancer clinical trials in Nevada: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Nevada, recruiting cancer studies are concentrated in Las Vegas, Reno, Henderson and Carson City, with sites in 4 other cities. 85 of the 140 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 140 recruiting Cancer trials in Nevada

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
PHASE2 Las Vegas, Nevada +4 sites NCT05997017
This trial is looking for women with advanced or recurrent endometrioid endometrial cancer to test a combination of two medications. Participants must have measurable disease and meet certain health criteria to join the study.
Recruiting
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
N/A Reno, Nevada +1 sites NCT05833360
This trial is looking for adult participants to help develop a new blood test that can find cancer early. Participants will provide a small blood sample and share their medical information.
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
PHASE3 Tucson, Arizona +4 sites NCT06136650
This trial is looking for men with metastatic castration-resistant prostate cancer who have been treated with one hormonal therapy before. Participants will receive either opevesostat with corticosteroids or other alternative treatments to see which is more effective.
Recruiting
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
PHASE3 Reno, Nevada +4 sites NCT07541079
This trial is looking for women with early breast cancer who have had problems with a previous hormonal treatment. If you join, you will switch to taking giredestrant as part of your cancer care.
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE3 Birmingham, Alabama +4 sites NCT04928846
This trial is looking for adults with a type of lung cancer who have already had treatment. Participants will receive either telisotuzumab vedotin or docetaxel through an IV every couple of weeks to see how well they work and how safe they are.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
PHASE3 Sacramento, California +4 sites NCT07513376
This trial is looking for people with high-risk non-small cell lung cancer that has been surgically removed. Participants will receive either one or two investigational treatments to help prevent the cancer from coming back after surgery.
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
PHASE3 Duarte, California +4 sites NCT07647328
This trial is looking for people with ER-positive, HER2-negative advanced breast cancer who have not received previous treatment. If you join, you will receive a combination of camizestrant and ribociclib until you decide to stop for any reason.
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
PHASE3 Gilbert, Arizona +4 sites NCT05894239
This trial is looking for people with advanced breast cancer that is HER2-positive and has a specific mutation. Participants will take a combination of medicines after their initial treatment.
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06764875
This trial is looking for individuals with advanced stomach cancer that tests positive for HER2. Participants will receive a combination of rilvegostomig, chemotherapy, and other treatments to see how well it works.
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3 Birmingham, Alabama +4 sites NCT07492641
This trial is looking for people with advanced breast cancer who have not been treated for it before. Participants will receive either BGB-43395 with letrozole or a different treatment option with letrozole.
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
PHASE3 Huntsville, Alabama +4 sites NCT07562152
This trial is looking for adults with advanced pancreatic cancer. Participants will receive a combination treatment to see how effective and safe it is compared to standard treatment.
Recruiting
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
PHASE3 Las Vegas, Nevada +4 sites NCT07683754
This trial is looking for adults with HER2-positive and HR-positive metastatic breast cancer. Participants will receive a specific treatment regimen that includes a drug called T-DXd, followed by maintenance therapy to manage their condition.
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
PHASE3 Phoenix, Arizona +4 sites NCT06170788
This trial is looking for adults with non-small cell lung cancer that is advanced and has specific characteristics. Participants will receive a combination of sacituzumab tirumotecan and pembrolizumab or pembrolizumab alone to see which treatment helps them live longer.
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
PHASE3 Little Rock, Arkansas +4 sites NCT06312137
This trial is looking for adults with a type of lung cancer called non-small cell lung cancer who did not have a complete response after surgery. Participants will receive medications to see if adding sacituzumab to pembrolizumab helps them stay cancer-free longer.
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
PHASE3 Phoenix, Arizona +4 sites NCT06925737
This trial is looking for men with advanced prostate cancer that has spread. By participating, I may receive a treatment called ifinatamab deruxtecan and help researchers learn if it works better than standard chemotherapy.
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
PHASE3 Fresno, California +4 sites NCT07195695
This trial is looking for adults who have had surgery for lung cancer and have specific genetic mutations. Participants will take either the new treatment zongertinib or standard care to see which is more effective at preventing cancer from returning.
Recruiting

Where the Cancer studies are in Nevada

  • Renown Regional Medical Center, Reno49 trials
  • Comprehensive Cancer Centers of Nevada, Las Vegas29 trials
  • OptumCare Cancer Care at Charleston, Las Vegas27 trials
  • OptumCare Cancer Care at Fort Apache, Las Vegas26 trials
  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas17 trials
  • Summerlin Hospital Medical Center, Las Vegas17 trials

Counts are recruiting studies listing at least one site in Nevada, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Nevada: common questions

How many Cancer clinical trials are recruiting in Nevada?
TrialFinder currently lists 140 recruiting Cancer clinical trials with study sites in Nevada. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Nevada?
Study sites for the Cancer trials listed on this page include Las Vegas, Reno. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Nevada?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Nevada also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Nevada?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Nevada.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →